ImmunoBiome

ImmunoBiome is a South Korean biotechnology company focused on developing next-generation live biotherapeutic products (LBPs) by leveraging the human microbiome. The company utilizes its proprietary Avatiome platform, which combines deep learning and immunological analysis to identify specific bacterial strains with potent therapeutic potential. Their approach focuses on the mechanistic understanding of how individual microbes interact with the host immune system, particularly through Toll-like receptor pathways. ImmunoBiome's pipeline includes candidates targeting oncology, inflammatory bowel disease, and other immune-mediated conditions. By isolating and characterizing high-potency strains, the company aims to overcome the limitations of traditional microbiome therapies and provide more predictable clinical outcomes.